<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_BGU_Israel_Parts1"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:BGU_Israel/Parts1">Page               </A></LI><LI><A href="/Talk:Team:BGU_Israel/Parts1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:BGU_Israel/Parts1&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:BGU_Israel/Parts1&amp;action=history">History               </A></LI><LI style="color:white;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:BGU_Israel/Parts1" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:BGU Israel/Parts1</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2014.igem.org</H3><DIV class="page1" id="top" style="white-space:nowrap; text-wrap:normal;"><NAV id="main_nav"><DIV id="main_wrap"><UL id="menu_ul"><LI><A href="https://2014.igem.org/Team:BGU_Israel/Team1">Team</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Team1">Team</A></LI><LI><A href="https://igem.org/Team.cgi?year=2014&amp;team_name=BGU_Israel">Official Team Profile</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Team/Collaboration">Collaboration</A></LI></UL><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project1">Project</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project1">Project Home</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Metabolic_Syndrome

">The Metabolic Syndrome</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Aspiration_Shift">Aspiration Shift</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Artificial_Exercise">Artificial Exercise</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Hormone_Workshop">Hormone Workshop</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Intelligent_Medication">Intelligent Medication</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Achivements">Achivements</A></LI><LI><A style="padding-left:3px" href="https://2014.igem.org/Team:BGU_Israel/Human_Practice1"> Policy &amp; Practices </A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice1">P &amp; P Home</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Bedouins">Bedouin Campaign</A></LI><LI><A href="
https://2014.igem.org/Team:BGU_Israel/Human_Practice/Spread_The_Word">Inner Doctor Campaign</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/University_Outreach">University Outreach</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Target">Target Population</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Policies">Laws &amp; Regulations</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Ethics">Ethics</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Project_Assessment">Project Assessment</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Parts1">Parts</A></LI><LI><A href="#">Modeling⇓</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Modeling/scRNA">scRNA Model</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Modeling/Aspiration_Shift">Aspiration Shift Model</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Notebook1">Notebook</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Notebook1">Notebook</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Safety/Lab_Protocols">Lab Protocols</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Safety1">Safety</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Attributions1">Attributions</A></LI></DIV></NAV><SECTION><DIV class="col3" style="margin-right:16px;height: 205px; width: 235px;"><H3 style="border-bottom:dashed;border-color:#000000">HSP70 Promoter</H3>
A human promoter that induces expression in response to heat stress.
</DIV><DIV class="col3" style="margin-right:16px; height: 205px; width: 235px;"><H3 style="border-bottom:dashed;border-color:#000000"> DsbA-L</H3>
An ER protein assisting in the synthesis of high molecular weight adiponectin.
         </DIV><DIV class="col3" style="margin-right:16px; height: 205px; width: 235px;"><H3 style="border-bottom:dashed;border-color:#000000"> Adiponectin</H3>
An insulin sensitizing hormone with beneficial metabolic effects.
         </DIV><DIV class="col3" style="margin-right:16px; height: 205px; margin-right: 0px; width: 235px;"><H3 style="border-bottom:dashed;border-color:#000000"> UCP1</H3>
 A trans-membrane mitochondrial protein which decreases the proton gradient generated in oxidative phosphorylation, and produces heat in the process.
        </DIV><DIV class="textCont" style="height: 450px;"><H3 style="border-bottom:dashed;border-color:#000000">HSP70 Promoter</H3><DIV class="col2" style="height:400px">Heat  shock proteins (HSP) are a key part of the heat shock response in almost all  organisms, from bacteria to humans. Their expression is induced drastically  when cells expose to stress such as elevated temperature, heavy metals or  starvation. The 70 kDa heat shock proteins (Hsp70s) are a family of conserved  ubiquitously expressed heat shock proteins. Like many other HSPs, HSP70 is an  important part of the cell's machinery of protein folding. Its role is to  prevent the aggregation of partially synthesized peptides or damaged proteins.
        <P>The  HSP70 promoter can be regulated by at list two distinct domains, a distal  domain which contains sequences responsive to heat shock and cadmium stress,  and proximal domain necessary for transcription stimulated by serum. The  activity of the promoter can be induced by moderate hyperthermia (39°C to  43°C), metal induction or by addition of serum after starvation (Wu, Kingston, &amp; Morimoto, 1986). </P></DIV><DIV class="col2"><P>Using  this promoter allows thermal induced expression in human cell lines. 
This  promoter’s sequence was taken from Invivogen pDRIVE-HSP70 (<A href="http://www.invivogen.com/pdrive-hsp70">http://www.invivogen.com/pdrive-hsp70</A>).  Since it contained two forbidden restriction sites, we changed the second base  from C to G and the 339th base from T to A.          </P><P><U><B>References:</B></U></P><P>Wu, B., Kingston, R., &amp; Morimoto, R. (1986). Human HSP70  promoter contains at least two distinct regulatory domains. <EM>Proceedings of  the National Academy of Sciences of the United States of America</EM>, <EM>83</EM>(February),  629–633. Retrieved from http://www.pnas.org/content/83/3/629.short</P></DIV></DIV><DIV class="textCont" style="height: 650px; margin-bottom: 12px;"><H3 style="border-bottom:dashed;border-color:#000000">Human DsbA-L Gene</H3><DIV class="col2"><P><STRONG><U>Brief introduction Of DsbA-L:</U></STRONG></P><P>DsbA-L  is a protein present in the ER (endoplasmic reticulum). Its main action is a Glutathione  S-Transferase action on the hormone adiponectin. It has the ability to  catalyze the conjugation of the reduced form of glutathione (GSH) to xenobiotic  substrates for the purpose of detoxification, and it helps with binding two  substrates with to s-s bonds and cellular detoxification.
        DsbA-L  is expressed mostly in adipose tissue, and its expression level is negatively  correlated with the obesity of mice and humans.
        DsbA-L has been shown to bind adiponectin and  increase the production of the HMW species, for that it can become a novel  therapeutic and industrial target.</P><P><STRONG><U>Modularization  of DsbA-L:</U></STRONG></P><P>The  DsbA-L sequence had iGEM Restriction sites that had to be change according to  iGEM protocol.
        In  position 131 G was changed to A to avoid Pst1 Site.
        In  position 446 A was changed to T to avoid Pst1 Site.
        In  position 467 A was changed to T to avoid Pst1 Site.
        In  position 545 C was changed to G to avoid Pst1 Site.</P>
All changes in nucleotides was done according to an  amino acid chart to maintain the same amino acids at the protein sequence  Level.

    </DIV><DIV class="col2"><P><STRONG><U>References:</U></STRONG></P><OL><LI>A disulfide-bond A  oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization, Meilian  Liua, Lijun Zhoub.  18302–18307PNAS  ,November 25, 2008 vol. 105  no. 47.</LI><LI>Fat-Specific DsbA-L  Overexpression Promotes Adiponectin Multimerization and Protects Mice From Diet-Induced  Obesity and Insulin Resistance. Meilian Liu, Ruihua Xiang, DIABETES, VOL. 61, NOVEMBER 2012.</LI><LI>Role of the Endoplasmic  Reticulum Chaperone DsbA-L Glutathione S-Transferase
       Activity  in the Assembly of Adipocyte Hormone Adiponectin . Dr Tsu-Shuen  Taso, kartchner, lavrel, Brianne, The University of Arizona library release,  may 2011.</LI><LI>Human GSTK1 on NCBI:
          http://www.ncbi.nlm.nih.gov/gene/373156</LI></OL></DIV></DIV><DIV class="textCont" style="height: 500px"><H3 style="border-bottom:dashed;border-color:#000000">Human AdipoQ Gene</H3><DIV class="col2" style="margin-left:10px; width:500px"><P><STRONG><U>Brief introduction Of  AdiopQ</U>:</STRONG></P><P>The  AdipoQ gene which codes for the protein adiponectin has domains similar to collagens X and VIII and complement factor C1q.  Adiponectin forms multimeric complexes that combine via its collagen domains to  create three major oligomeric forms: a low molecular weight (LMW) trimer, a  middle - molecular weight (MMW) hexamer, and high molecular weight (HMW) 12-18-  mer Adiponectin.
          Normally  it is expressed exclusively in adipose tissues from which it is secreted to the  blood stream. It directly sensitizes the body to insulin and has an important  role in lipid and glucose metabolism regulation. Therefore adiponectin  represents a potential therapeutic target to fighting obesity-linked diseases  characterized by insulin resistance and the Metabolic Syndrom.</P>
Furthermore low levels of serum Adiponectin is  highly related with occurrence of abdominal obesity, insulin resistance, type 2  diabetes, and the metabolic syndrome
 
      </DIV><DIV class="col2" style="margin-left:20px"><P><STRONG><U>References:</U></STRONG></P><OL><LI>Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K., &amp; Tobe, K.  (2006). Review series Adiponectin and adiponectin receptors in insulin  resistance , diabetes , and the metabolic syndrome. <EM>J Clin Invest.</EM>, <EM>116</EM>(7),  1784–1792. doi:10.1172/JCI29126.1784</LI><LI>Human adiponectin on NCBI :  http://www.ncbi.nlm.nih.gov/gene/9370</LI></OL></DIV></DIV><DIV class="textCont" style="height: 500px; margin-bottom: 12px;"><H3 style="border-bottom:dashed;border-color:#000000">UCP1 (Uncoupling protein 1)</H3><DIV class="col2"><P><STRONG><U>Brief introduction Of UCP1</U></STRONG></P>

       A transmembrane protein naturally present in mitochondria of brown adipose tissue. The gene itself is found in the nuclear genome, and after translation it is sent to the mitochondria.

<P>UCP1 increases the permeability of the inner mitochondrial membrane to protons, allowing them to move from the inner membrane space to the mitochondrial matrix, bypassing ATP synthase.This process weakens the coupling of the electron transport chain to the production of ATP.  In an attempt to raise the pH gradient negatively affected by UCP1, a fast oxidation of substrates occurs while the synthesis rate of ATP stays low and oxidation energy is released as heat instead.</P><P>UCP1 is activated in the brown fat cell by fatty acids and is inhibited by nucleotides. </P></DIV><DIV class="col2" style="margin-left:20px"><P><STRONG><U>References:</U></STRONG></P><OL><LI>Bugianesi, E., Moscatiello, S., Ciaravella, M.F. &amp; Marchesini, G.  (2010).  <STRONG>Insulin resistance in  nonalcoholic fatty liver disease.  </STRONG>Curr  Pharm Des 16: 1941-1951</LI><LI>Kozak, L.P. &amp; Anunciado-Koza,  R. (2008). <STRONG>UCP1: its involvement and utility in obesity</STRONG>. Int. J. Obes., 32 (Suppl. 7), pp. S32–S38</LI><LI>Wu,  B.J., Kingston, R.E. &amp; Morimoto, R.I. (1986). <STRONG>Human HSP70 promoter  contains at least two distinct regulatory domains</STRONG></LI></OL></DIV></DIV></SECTION></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2014.igem.org/Team:BGU_Israel/Parts1">http://2014.igem.org/Team:BGU_Israel/Parts1</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:BGU_Israel/Parts1" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:BGU_Israel/Parts1" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:BGU_Israel/Parts1&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:BGU_Israel/Parts1&amp;oldid=373783" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2014.igem.org:Privacy_policy" title="2014.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2014.igem.org:General_disclaimer" title="2014.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>